Join Growin Stock Community!

Milestone pharmaceuticals inc.MIST.US Overview

US StockHealthcare
(No presentation for MIST)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MIST AI Insights

MIST Overall Performance

MIST AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MIST Recent Performance

-0.88%

Milestone pharmaceuticals inc.

0.05%

Avg of Sector

-0.31%

S&P500

MIST PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MIST Key Information

MIST Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MIST Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Price of MIST

MIST FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MIST Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.68
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
77.32
PB Ratio
7.17
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.68
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
77.32
PB Ratio
7.17
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is MIST's latest earnings report released?

    The most recent financial report for Milestone pharmaceuticals inc. (MIST) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MIST's short-term business performance and financial health. For the latest updates on MIST's earnings releases, visit this page regularly.

  • How much debt does MIST have?

    As of the end of the reporting period, Milestone pharmaceuticals inc. (MIST) had total debt of 57.21M, with a debt ratio of 0.65. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MIST have?

    At the end of the period, Milestone pharmaceuticals inc. (MIST) held Total Cash and Cash Equivalents of 46.69M, accounting for 0.53 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is MIST's EPS continuing to grow?

    According to the past four quarterly reports, Milestone pharmaceuticals inc. (MIST)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.12. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MIST?

    Milestone pharmaceuticals inc. (MIST)'s Free Cash Flow (FCF) for the period is -9.75M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 38.85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.